Untitled

Drug Addiction Treatment - References - Master List

Cognitive Behavioral Treatments - Kathleen Carroll
Biology of Reward Mechanisms - Eliot Gardner
Contingency Management - Stephen Higgins
Treatment Outcome Research - A. Thomas Mclellan
Anti-Cocaine Catalytic Antibodies - Donald Landry
Pharmacological Treatment of Drug Addiction - Frances Levin
Brain Imaging & Substance Abuse Research - Nora Volkow

Cognitive Behavioral Treatments - Kathleen Carroll

Carroll, K.M. (1998). A Cognitive-Behavioral Approach: Treating Cocaine Addiction. NIH Publication 98-4308. Rockville, MD: National Institute on Drug Abuse.

Carroll, K.M. (1996). Relapse prevention as a psychosocial treatment approach: A review of controlled clinical trials. Experimental and Clinical Psychopharmacology, 4, 46-54. Reprinted in G.A. Marlatt & G.R. VandenBos (eds.), Addictive Behaviors: Readings on etiology, prevention and treatment (pp. 697-716). Washington, DC: American Psychological Association, 1997.

Carroll, K.M. (in press). Behavioral and cognitive behavioral treatments. In B.S. McCrady & E.E. Epstein (eds.), Addictions: A Comprehensive Guidebook for Practitioners. New York: Oxford University Press.

Carroll, K.M., Nich, C., Ball, S.A., McCance, E., & Rounsaville, B.J. (1998). Treatment of cocaine and alcohol dependence with psychotherapy and disulfiram. Addiction, 93, 713-728.

Carroll, K.M., Rounsaville, B.J., Gordon, L.T., Nich, C., Jatlow, P.M., Bisighini, R.M., and Gawin, F.H. (1994). Psychotherapy and pharmacotherapy for ambulatory cocaine abusers. Archives of General Psychiatry, 51, 177-187.

Carroll, K.M., Rounsaville, B.J., Nich, C., Gordon, L.T., Wirtz, P.W., & Gawin, F.H. (1994). One year follow-up of psychotherapy and pharmacotherapy for cocaine dependence: Delayed emergence of psychotherapy effects. Archives of General Psychiatry, 51, 989-997.

Kadden, R., Carroll, K.M., Donovan, D., Cooney, N., Monti, P., Abrams, D., Litt, M., & Hester, R. (1992). Cognitive-behavioral coping skills therapy manual: A clinical research guide for therapists treating individuals with alcohol abuse and dependence. NIAAA Project MATCH Monograph Series Volume 3, DHHS Publication No. (ADM) 92-1895. Rockville, MD: National Institute on Alcohol Abuse and Alcoholism.

Maude-Griffin, P..M., Hohenstein, J..M., Humfleet, G.L., Reilly, P.M., Tusel, D.J., & Hall, S.M. (1998). Superior efficacy of cognitive-behavioral therapy for crack cocaine abusers: Main and matching effects. Journal of Consulting and Clinical Psychology, 66, 832-837.

McKay, J.R., Alterman, A.I., Cacciola, J.S., Rutherford, M.J., O'Brien, C.P. & Koppenhaver, J. (1997). Group counseling versus individualized relapse prevention aftercare following intensive outpatient treatment for cocaine dependence. Journal of Consulting and Clinical Psychology, 65, 778-788.

Project MATCH Research Group (1997). Matching Alcohol Treatments to Client Heterogeneity: Project MATCH post-treatment drinking outcomes. Journal of Studies on Alcohol, 58, 7-29.

Carroll, K.M. (1998). A Cognitive-Behavioral Approach: Treating Cocaine Addiction. NIH Publication 98-4308. Rockville, MD: National Institute on Drug Abuse.

Carroll, K.M. (1996). Relapse prevention as a psychosocial treatment approach: A review of controlled clinical trials. Experimental and Clinical Psychopharmacology, 4, 46-54. Reprinted in G.A. Marlatt & G.R. VandenBos (eds.), Addictive Behaviors: Readings on etiology, prevention and treatment (pp. 697-716). Washington, DC: American Psychological Association, 1997.

Carroll, K.M., Nich, C., Ball, S.A., McCance, E., & Rounsaville, B.J. (1998). Treatment of cocaine and alcohol dependence with psychotherapy and disulfiram. Addiction, 93, 713-728.

Kadden, R., Carroll, K.M., Donovan, D., Cooney, N., Monti, P., Abrams, D., Litt, M., & Hester, R. (1992). Cognitive-behavioral coping skills therapy manual: A clinical research guide for therapists treating individuals with alcohol abuse and dependence. NIAAA Project MATCH Monograph Series Volume 3, DHHS Publication No. (ADM) 92-1895. Rockville, MD: National Institute on Alcohol Abuse and Alcoholism.

Project MATCH Research Group (1997). Matching Alcohol Treatments to Client Heterogeneity: Project MATCH post-treatment drinking outcomes. Journal of Studies on Alcohol, 58, 7-29.

Biology of Reward Mechanisms - Eliot L. Gardner

Ahmed, S.H. & Koob, G.F. Transition from moderate to excessive drug intake: change in hedonic set point. Science 282:298-300 (1998).

Gardner, E.L. Brain reward mechanisms. In Lowinson, J.H., Ruiz, P., Millman, R.B. & Langrod, J.G. (Eds), Substance Abuse: A Comprehensive Textbook, 3rd ed. Baltimore: Williams & Wilkins, pp.51-85 (1997).

Gardner, E.L. (Ed) The Neurobiology of Drug Addiction/Dependency. Seminars in the Neurosciences. London: Academic Press (1993).

Gardner, E.L. & David, J. The neurobiology of chemical addiction. In Elster, J. & Skog, O.J. (Eds), Getting Hooked: Rationality and the Addictions. Cambridge, England: Cambridge University Press, pp.93-136 (1999).

Gardner, E.L. & Lowinson, J.H. Drug craving and positive/negative hedonic brain substrates activated by addicting drugs. Seminars in the Neurosciences 5:359-368 (1993).

Koob, G.F. & Le Moal, M. Drug abuse: hedonic homeostatic dysregulation. Science 278:52-58 (1997).

Kornetsky, C. Brain-stimulation reward: a model for the neuronal bases for drug-induced euphoria. National Institute on Drug Abuse Research Monograph Series 62:30-50 (1985).

Wise, R.A. & Rompre, P.-P. Brain dopamine and reward. Annual Review of Psychology 40:191-225 (1989).

Wise, R.A. Neurobiology of addiction. Current Opinion in Neurobiology 6:243-251 (1996).

Wise, R.A. Addictive drugs and brain stimulation reward. Annual Review of Neuroscience 19:319-340 (1996).

Wise R.A. Drug activation of brain reward pathways. Drug and Alcohol Dependence 51:13-22 (1998).

Contingency Management with Cocaine Dependent & Special Treatment Populations - Stephen T. Higgins

Higgins ST, Budney AJ, Bickel WK, et al: Incentives improve outcome in outpatient behavioral treatment of cocaine dependence. Arch Gen Psychiatry (1994), 51:568-576.

Higgins ST: Some potential contributions of reinforcement and consumer-demand theory to reducing cocaine use. Addictive Behaviors (1996), 21:803-816.

Silverman K, Higgins ST, Broomer RK, et al: Sustained cocaine abstinence in methadone maintenance patients through voucher-based reinforcement therapy. Arch Gen Psychiatry (1996), 53:409-415.

Anti-Cocaine Catalytic Antibodies - Donald W. Landry

1. Bones, K.F., B.H. Wainer, F.W. Fitch, R.M. Rothbert and C.R. Schuster. Changes in heroin self-administration by a rhesus monkey after morphineimmunization. Nature 252:708-718, 1074.

2. Pollack, S.J., J.W. Jacobs and P.G. Schultz. Selective chemical catalysis by an antibody. Science 234:1570-1574,1986.

3. Benkovic, S.J., A.D. Napper and R.A. Lerner. Catalysis of a stereospecific bimolecular amide synthesis by an antibody. Proc. Natl. Acad. Sci. USA 85:5355-5358,1988.

4. Misra, A.L., P.K. Nayak, R. Bloch, and S.J. Mule. Estimation and disposition of [³H]benzoyecgonine and pharmacological activity of some cocaine metabolites.J. Pharm. Pharmacol. 27:784-786,1975.

5. Landry, D.W., M. Akabas, C. Redhead, A. Edelman, E. Cragoe, Q. Al-Awqati. Purification and reconstitution of chloride channels from kidney and trachea. Science 255:1469-1472, 1989

6. Yang, G., J. Chun, H. Arakawa-Uramoto, M.A. Gawinowicz, K. Zhao, and D.W. Landry. Anti-cocaine catalytic antibodies: A synthetic solution to improved diversity. J. Am. Chem. Soc. 118(25):5881-5890,1996.

7. Mets, B., G. Winger, C. Cabrera, S. Seo, S. Jamdar, G. Yang, K. Zhao, R.J. Breiscoe, J.H. Woods and D.W. Landry. A catalytic antibody against cocaine prevents cocaine's reinforcing and toxic effects in rats. Proc. Natl. Acad. Sci. USA 95:10176-10181,1998.

Pharmacological Treatment of Drug Addiction - Frances Levin

Ball JC, and Ross A. The effectiveness of methadone maintenance treatment. 1991;
New York: Springer-Verlag, 283.

Becker H.C., and Hale, R.L. Repeated Episodes of Ethanol Withdrawal Potentiate the
Severity of Subsequent Withdrawal Seizures: An Animal Model of Alcohol Withdrawal
"Kindling". Alcohol Clin Exp Res. 1993; 17:94-98.

Brady K., Anton R., Ballenger JC et al. Cocaine abuse among schizophrenic patients.
American Journal of Psychiatry. 1990; 147:1164-1167.

Brown M.E., Anton R.F., Malcolm R., and Ballenger J.C. Alcohol Detoxification and
Withdrawal Seizures: Clinical Support for a Kindling Hypothesis. Biol Psychiatry. 1988;
23: 507-514.

Capelhorn JRM, and Bell J. Methadone dosage and retention of patients in
maintenance treatment. Medical Journal of Australia. 1991; 154: 195-199.

Charney DS, Sternberg DE, Kleber HD, Henninger GR, and Redmond DE. The clinical
use of clonidine in abrupt withdrawal from methadone. Archives of General Psychiatry.
1981; 38:1273-1277.

Chick J, Gough K, Falkowski W. Disulfiram treatment of alcoholism. Br J Psychiatry.
1992; 161:84-89.

Compton PA, Wesson DR, Charuvastra VC, Ling W. Buprenorphine as a
pharmacotherapy for opiate addiction. Am J Addict. 1996;5:220-230.

Croop Rs, Faulkner EB, Labriola DF. The safety profile of naltrexone in the treatment
of alcoholism: results from a multicenter usage study. Arch Gen Psychiatry.
1997;54:1130-1135.

Dole VP, and Nyswander M. A medical treatment for diacetylmorphine (heroin)
addiction- A clinical trial with methadone hydrochloride. Journal of the American
Association. 1965; 193(8):646-650.

Fudala PJ, Vocci F, Montgomery A, and Trachtenberg AI. Levomethadyl acetate
(LAAM) for the treatment of opioid dependence: A multisite, open-label study of LAAM
safety and an evaluation of the product labeling and treatment regulations. Journal of
Maintenance in the Addictions. 1997; 1(2): 9-39.

Fuller RK, Branchley L, Brightwell DR, et al. Disulfiram treatment of alcoholism: a
Veteran's Administration cooperative study. JAMA. 1986;256:1449-1455.

Gold ME, Redmond DC, and Kleber HD. Clonidine blocks acute opiate-withdrawal
symptoms. Lancet. 1978; 2:599-602.

Grabowski J., Rhoades H., Schmitz J., Davis C., Creson D., and Kirby K. Fluoxetine is
ineffective for treatment of cocaine dependence or concurrent opiate and cocaine
dependence: Two placebo-controlled, double-blind trials. Journal of Clinical
Psychopharmacology. 1995; 15: 163-174.

Higgins ST, Budney AJ, Bickel WK et. al. Disulfiram therapy in patients abusing
cocaine and alcohol. American Journal of Psychiatry. 1993; 150(4): 675-676.

Himmelsbach CK. Clinical studies of drug addiction: Physical dependence, withdrawal
and recovery. Archives of Internal Medicine. 1942;69:766-772.

Jasinski DR, Pevnick JS, and Griffith JD. Human pharmacology and abuse potential of
the analgesic buprenorphine. Archives of General Psychiatry. 1978; 35:501-516.

Johnson RE, Fudala PJ, and Jaffe JH. A controlled trial of buprenorphine for opioid
dependence. Journal of the American Medical Association. 1992; 267:2750-2755.

Kessler RC, McGonagle KA, Zhao S et al. Lifetime and 12-month prevalence of
DSM-III-R psychiatric disorders in the United States. Results from the National
Comorbidity Survey. Archives of General Psychiatry. 1994; 51(1):8-19.

Kolar A., Brown B., Weddington W., Haertzen C., Michaelson B., and Jaffe J.
Treatment of cocaine dependence in methadone maintenance clients: a pilot study
comparing the efficacy of desipramine and amantadine. International Journal of the
Addictions. 1992; 27: 849-868.

Kosten TR, Krystal JH, Charney DS, Price LH, Morgan CH, and Kleber, HD. Rapid
detoxification from opioid dependence. American Journal of Psychiatry. 1989;
146:1349.

Kosten TR, Schottenfeld R, Ziedonis D, and Falcioni J. Buprenorphine versus
methadone maintenance for opioid dependence. Journal of Nervous and Mental
Disease. 1993.

Kranzler HR, Burleson JA, Korner P, et al. Placebo-controlled trial of fluxotine as an
adjunct to relapse prevention in alcoholics. Am J Psychiatry. 1995;152:391-397.

Levin FR, Lehman AF. Meta-analysis of desipramine as an adjunct in the treatment of
cocaine addiction. J Clin Psychopharmacol. 1991;11:374-378.

Levin FR, Evans SM, McDowell DM, and Kleber HD. Methylphenidate treatment for
cocaine abusers with adult attention-deficit/hyperactivity disorder: A Pilot Study. Clin
Psychiatry. 1998;56:6/June

Ling W, Rawson RA, Compton PA. Substitution pharmacotherapies for opioid
addiction: from methadone to LAAM and buprenorphine. J Psychoactive Drugs. 1994;
26(2):119-128.

Littleton J. Acamprosate in alcohol dependence: how does it work? Addiction.
1995;99:1179-1188.

Malcolm R, Ballenger JC, Sturgis ET, Anton R. Double blind controlled trial comparing
carbamazepine to oxazepam treatment of alcohol withdrawal. Am J Psychiatry.
1989;146:617-621.

McLellan AT, Arndt IO, Metzger DS, Woody GE, and O'Brien CP. The effects of
psychosocial services in substance abuse treatment. Journal of the American Medical
Association 1993; 269(15):1953-1959.

McLellan AT, Grisson GR, Zanis D, Randall M, Brill P, and O'Brien CP.
Problem-service 'matching' in addiction treatment. A prospective study in 4 programs.
Archives of General Psychiatry. 1997; 54(8): 730-735.

Montoya ID, Levin, Fr, Fudala, P, and Gorelick, DA. Double-blind comparison of
carbamazepine and placebo for treatment of cocaine dependence. Drug and Alcohol
Dependence. 1995; 38: 213-219

O'Connor PG, Kosten TR. Rapid and ultrarapid opioid detoxification techniques. JAMA.
1998;279:229-234.

O'Malley SS, Jaffe AJ, Chang G, Schottenfeld RS, Meyer RE, Rounsaville B.
Naltrexone and coping skills therapy for alcohol dependence. Arch Gen Psychiatry.
1992;49:881-887.

Payte JT. Methadone maintenance treatment: The first thirty years. Journal of
Psychoactive Drugs. 1997b; 29(2): 149-153.

Regier DA, Fanner ME, Rae DS. Comorbidity of mental disorders with alcohol and
other drug abuse. JAMA. 1990;264:2511-2518.

Rounsaville BJ, Anton SF, Carroll K, Bude D. et al. Psychiatric diagnoses of
treatment-seeking cocaine abusers. Archives of General Psychiatry. 1991;48: 43-51.

Sass H, Soyka M, Mann K, Zieglgansberger W. Relapse prevention by acamprosate:
results from a placebo-controlled study on alcohol dependence. Arch Gen Psychiatry.
1996;53:673-680.

Senay EC. Methadone maintenance treatment. Int J Addictions. 1985;20:803-821.

Senay EC, Dorus W, Goldberg F, and Thornton W. Withdrawal from methadone
maintenance. Archives of General Psychiatry. 1977; 34:361-367.

Shaner A., Khalsa ME, Roberts L, Wilkins J. et al. Unrecognized cocaine use among
schizophrenic patients. American Journal of Psychiatry. 1993; 150: 758-762.

Swift, RM. Pharmacologic treatments for drug and alcohol dependence: Experimental
and standard therapies. Psychiatry Annals. 1998;28:12/December.

Sullivan, J.T., M.B., Ch.B., Sykora, K., M.Sc., Schneiderman, J., Naranjo, C.A., and
Sellers, E.M. Assessment of Alcohol Withdrawal: the revised clinical institute
withdrawal assessment for alcohol scale (CIWA-Ar). British Journal of Addiction. 1989;
84:1353-1357.

Vining E, Kosten TR, and Kleber HD. Clinical utility of rapid clonidine-naltrexone
detoxification for opioid abusers. British Journal of Addiction. 1988; 83:567-575.

Volpecelli JR, Alterman AI, Hayashida M, O'Brien CP. Naltrexone in the treatment of
alcohol dependence. Arch Gen Psychiatry. 1992;49:876-880.

Treatment Outcome Research on Drug Addiction - A. Thomas McLellan

McLellan AT, Woody GE, Metzger D, et al: Evaluating the effectiveness of addiction treatments: Reasonable expectations, appropriate comparisons. The Milbank Quarterly (1996), 74:51-85.

O'Brien CP and McLellan AT: Myths about the treatment of addiction. American Society of Addiction Medicine (1998), 310-314.

McLellan AT, Hagan TA, Levine M, et al: Supplemental social services improve outcomes in public addiction treatment. Addiction (1998), 93:1489-1499.

Brain Imaging & Substance Abuse Research - Nora Volkow

Balster RL, Schuster CR (1973) Fixed-interval schedule of cocaine reinforcement:
effects of dose and infusion duration. J Exp Anal Behav 20:119-129

Ding Y-S, Fowler JS, Volkow ND, Gatley SJ, Logan J, Dewey S, Alexoff D, Wolf AP
(1994) Pharmacokinetics and in vivo specificity of [¹¹C]d1-threo-methylphenidate for
the presynaptic dopaminergic neuron Synapse 18:152-160

Fowler JS, Volkow ND, Logan J, Gatley SJ, Pappas N, King P, Ding Y-S, Wang GJ
(1998) Measuring dopamine transporter occupancy by cocaine: Radiotracer
considerations. Synapse 28:111-116

Klein RG, Abikoff H, Klass E, Ganeles D, Seese LM and Pollack S (1997) Clinical
efficacy of methylphenidate in conduct disorder with and without attention deficit
hyperactivity disorder. Arch Gen Psychiatry 54:1073-1080

Koob GF, Bloom FE (1988) Cellular and molecular mechanism of drug
dependence. Science 242:715-723

Madras BK, Fahey MA, Bergman J, Canfield DR, Spealman RD (1989) Effects of
cocaine and related drugs in non-human primates. I [3H]cocaine binding sites in
caudate-putamen. J Pharmacol Exp Ther 251:131-141

Parran TV, Jasinski DR (1991) Intravenous methylphenidate abuse: prototype for
prescription drug abuse. Arch Intern Med 151:781-783

Pontieri FE, Tanda G, Orzi F, Di Chiara G (1996) Effects of nicotine on the nucleus
accumbens and similarity to those of addictive drugs. Nature 382:255-257

Ritz MC, Lamb RJ, Goldberg SR, Kuhar MJ (1987) Cocaine receptors on dopamine
transporters are related to self-administration of cocaine. Science 237:1219-1223

Schweri MM, Skolnick P, Rafferty MF, Rice KC, Janowsky AJ, Paul SM(1985)
[3H]Threo-(+/-)-methylphenidate binding to 3,4-dihydroxyphenyl ethylamine uptake
sites in corpus striatum: Correlation with the stimulant properties of ritalinic acid
esters. J Neurochem 45:1062-1070

Swanson JM, Seargeant JA, Taylor E, Sonuga-Barke EJS, Jensen PS, Cantwell DP
(1998) Attention deficit disorder and hyperkinetic disorder. Lancet 351:429-433

Volkow ND, Ding U, Fowler JS, Wang GJ, Logan J, Gatley JS, Dewey SL, Ashby C,
Lieberman J, Hitzemann R, Wolf AP (1995) Is methylphenidate like cocaine?
Studies on their pharmacokinetics and distribution in human brain. Arch Gen
Psychiatry 52:456-463

Volkow ND, Fowler JS, Gatley JS, Logan J, Wang G-J, Ding Y-S, Dewey SL (1996)
Evaluation of the human brain dopamine system with PET. J Nucl Med
37:1242-1256

Volkow ND, Rosen B, Farde L (1997a) Imaging the living human brain: Magnetic
resonance imaging and positron emission tomography. Proc Natl Acad Sci USA
94:2787-2788

Volkow ND, Wang GJ, Fischman MW, Foltin RW, Fowler JS, Abumrad NN, Vitkun
S, Logan J, Gatley SJ, Pappas N, Hitzemann R, Shea K (1997b) Relationship
between subjective effects of cocaine and dopamine transporter occupancy. Nature
386:827-830

Volkow ND, Wang G-J, Fowler JS, Gatley JS, Logan J, Ding Y-S, Hitzemann R,
Pappas N (1998a) Dopamine, transporter occupancies in the human brain induced
by therapeutic doses of oral methylphenidate. Am J Psychiatry 155:1325-1331

Volkow ND, Wang GJ, Fowler JS, Gatley SJ, Logan J, Ding Y-S, Dewey SL,
Hitzemann R, Gifford A, Pappas NR (1999) Blockade of striatal dopamine
transporters by intravenous methylphenidate is not sufficient to induce self reports
of "High". J Pharmacol Exp Ther 288:14-20.

Volkow, N.D., Wang, G.J., Fowler, J.S., Fischman M., Foltin, R., Abumrad, N.N.,
Gatley, S.J., Logan, J., Wong C., Gifford, A., Hitzemann, R. and Pappas, N. (in
press) .Methylphenidate and cocaine have a similar in vivo potency to block
dopamine transporters in the human brain. Life Sciences.